Ancanex Pharma Trading FZCO, Building A1, Dubai Digital Park, Dubai Silicon Oasis, Dubai (2026)

17/03/2026

🌟 Peginterferon Alfa-2a 180 mcg Pre-Filled Syringe – Long-Acting Antiviral Therapy

A pegylated interferon formulation developed for sustained antiviral activity in the treatment of chronic viral infections. Peginterferon alfa-2a provides prolonged systemic exposure, enabling once-weekly administration and improved patient adherence compared to conventional interferon therapies.

Widely utilized in the management of chronic hepatitis B (HBV) and hepatitis C (HCV), this therapy plays a critical role in immune modulation and viral suppression protocols.

💊 Dosage Form: Solution for injection (pre-filled syringe)

💉 Administration: Subcutaneous use

📦 Presentation: Single-dose pre-filled syringe

🧬 Active Substance: Peginterferon alfa-2a 180 mcg / 0.5 mL

🌡 Storage: Cold chain recommended (2–8°C)

⸻

✅ Key Highlights

• Pegylated interferon with extended half-life

• Once-weekly dosing regimen improves compliance

• Proven role in chronic HBV & HCV treatment protocols

• Supports immune-mediated viral clearance

• High global demand in hospital and specialty care settings

• Suitable for named patient supply and international sourcing

⸻

🌍 Global Supply & Sourcing Expertise

At Ancanex Pharma, we specialize in sourcing and supplying specialty antiviral and critical care medicines through a trusted international network.

✔ WHO-GMP compliant manufacturing sources

✔ Access to regulated & semi-regulated market supply chains

✔ Flexible sourcing: branded & generic alternatives

✔ Support with documentation

✔ End-to-end logistics coordination (cold chain available)

✔ Reliable supply for distributors, hospitals & procurement companies

We help our partners secure the right product, from the right source, at the most competitive conditions.

⚠️ Disclaimer: This post is for professional and informational purposes only. Product availability may vary depending on market regulations.

16/02/2026

🌍 Expanding Access to Advanced CFTR Modulator Therapies

At Ancanex, we collaborate with trusted global distributors to support access to advanced combination CFTR modulator therapies used in the management of cystic fibrosis.

These therapies may be available in different strength configurations suitable for both pediatric and adult patient populations, based on physician guidance and clinical requirements.

Active components in such combination therapies typically include:
• Elexacaftor
• Tezacaftor
• Ivacaftor

They are designed to improve CFTR protein function and support better clinical outcomes in eligible cystic fibrosis patients.

🤝 Our Role in Global Supply

Through our international sourcing and distribution network, Ancanex can assist partners with:
• Reliable sourcing via verified distributors
• Support for pediatric & adult strength requirements
• Documentation and regulatory-compliant supply pathways
• Cold-chain coordination and global logistics solutions
• Access to both branded and equivalent specialty treatments

🌐 Ancanex Vision – “Anti Cancer Export” (AnCanEx)

While oncology access is central to our mission, we also extend our support to rare disease therapies where global access remains limited.
Our priority is always the same: helping patients reach quality treatments through responsible and compliant supply channels.

We thank our partners and distributors worldwide who share the same goal — improving access to life-changing therapies.

📩 Distributors, hospitals, and procurement teams seeking reliable sourcing for cystic fibrosis and other specialty therapies are welcome to connect with us.

13/02/2026

🌍 Expanding Global Access to Oncology & Specialty Medicines

At Ancanex Pharma Trading FZCO, we work closely with a wide network of WHO-GMP, EMA, FDA certified manufacturers and trusted global distributors to ensure reliable sourcing and supply of both generic and branded oncology and specialty medicines.

Through our established partnerships, we support our clients not only in identifying the most suitable and compliant production facilities, but also in managing documentation, regulatory alignment, and end-to-end logistics coordination.

When projects require, we can facilitate manufacturing from WHO-GMP facilities as well as connect partners with EMA- and FDA-compliant production environments through our extended global network.

Our name, AnCanEx, reflects our core philosophy: Anti-Cancer Export. We are committed to helping our partners secure high-quality, cost-effective medicines and, ultimately, to improving patient access to life-saving treatments worldwide.

Whether you are a distributor seeking a reliable manufacturing source, or a manufacturer looking to expand into new markets, Ancanex acts as a strategic bridge connecting the right products, the right partners, and the right markets.

We sincerely thank our partners who share this vision and collaborate with us to make quality oncology and specialty medicines more accessible across the globe.

— Ancanex Pharma Trading FZCO

12/02/2026

🌍 Thank You, WHX / Arab Health 2026 — See You in 2027!

We would like to extend our sincere thanks to everyone who connected with Ancanex Pharma Trading FZCO during WHX / Arab Health 2026 in Dubai.

It was a pleasure meeting healthcare professionals, distributors, suppliers, and industry partners from around the world. The conversations, insights, and new opportunities shared during the event were truly valuable.

We appreciate every meeting, every introduction, and every meaningful discussion.

🤝 Thank you to all who visited us and took the time to explore potential collaboration.

We look forward to strengthening these connections and continuing our global healthcare partnerships.

📍 See you again in 2027!

— Ancanex Pharma Trading FZCO

04/02/2026

🌍 Ancanex at World Health Expo — Dubai 🇦🇪

We are excited to announce that Ancanex Pharma Trading FZCO will be participating in the World Health Expo 2026 in Dubai!
This global healthcare event brings together leading pharmaceutical professionals, distributors, healthcare systems, and industry partners under one roof to share insights, innovations, and collaborative opportunities.

📅 Event: World Health Expo — Healthcare
📍 Location: Dubai World Trade Centre, UAE

As a global pharmaceutical trading partner, we look forward to:
✨ Connecting with international wholesalers and distributors
✨ Exploring new sourcing and supply chain opportunities
✨ Strengthening partnerships across healthcare markets
✨ Supporting access to essential and specialty medicines worldwide

📩 Interested in meeting with us at the Expo?
Send us a message or contact our business development team to schedule a time.

We hope to see you there!

22/01/2026

🌟 Targeted Anti-Angiogenic Therapy – 12 mg Capsules

Anlotinib Hydrochloride is an oral small-molecule tyrosine kinase inhibitor (TKI) developed for the management of certain solid tumors. It exerts its therapeutic effect by inhibiting multiple receptors involved in tumor angiogenesis and proliferation, supporting disease control through targeted anti-angiogenic mechanisms.

💊 Dosage Form: Anlotinib Hydrochloride Capsules
📦 Strength: 12 mg x 21 Tablet
🧬 Therapeutic Area: Oncology – Targeted Therapy
🌡 Storage: Ambient

⸻

✅ Key Highlights

• Multi-target tyrosine kinase inhibition
• Anti-angiogenic and anti-tumor activity
• Oral capsule formulation for outpatient use
• Used in oncology treatment protocols under approved indications
• Frequently requested by hospitals and oncology centers in regulated markets

⸻

🌍 Supporting Global Access

Ancanex Pharma Trading FZCO supports licensed distributors, hospitals, and specialty pharmacies with access to oncology and hard-to-source medicines through compliant international wholesale and export channels.

⸻

⸻

⚠️ Disclaimer: This post is for professional and informational purposes only.

07/01/2026

🌟 Sunvozertinib 150 mg Tablets – Targeted Therapy Option

Sunvozertinib is an oral targeted therapy developed for specific oncologic indications, designed to support precision treatment approaches in eligible patients. This small-molecule therapy is formulated to selectively act on its intended molecular pathway, supporting modern targeted oncology care strategies.

💊 Dosage Form: 150 mg Film-Coated Tablets
📦 Pack Size: 14 Tablets per box
🧬 Therapeutic Area: Oncology – Targeted Therapy

✅ Key Highlights

• Oral targeted treatment option
• Developed to address defined molecular oncologic profiles
• Supports precision medicine approach in cancer care
• Manufactured under internationally recognized pharmaceutical quality standards
• Required by hospitals, oncology centers, and specialty distributors

🌍 Supporting Global Access

Ancanex Pharma Trading FZCO helps hospitals, clinics, and licensed distributors access specialty and hard-to-source medicines through secure and compliant international wholesale channels.

⚠️ Disclaimer: This post is for professional and informational purposes only.

05/01/2026

🌟 Purine Analog Therapy for Hematologic Conditions – 10 mg Tablets

Cladribine is a purine nucleoside analogue used in the treatment of specific hematologic and immune-mediated conditions. It works by selectively targeting and reducing lymphocytes, helping stabilize disease activity and control abnormal immune responses.

💊 Dosage Form: Cladribine 10 mg tablets
📦 Pack Size: 6 tablets
🧬 Therapeutic Area: Hematology / Autoimmune Disorders
💉 Mechanism: Selective lymphocyte depletion via DNA synthesis disruption

✅ Key Highlights

• Purine analog with targeted immunomodulatory effect
• Widely used in hematology and autoimmune treatment settings
• Oral dosing convenience where applicable
• High global demand in specialty medicine supply chains
• Commonly requested by hospitals, specialty clinics, and treatment centers

🌍 Supporting Global Access

Ancanex Pharma Trading FZCO supports wholesalers, hospitals, government tenders, and licensed distributors with access to specialty and hard to source medicines through secure supply channels.

⚠️ Disclaimer: This post is for professional and informational purposes only.

25/12/2025

🎆 Happy New Year 2026!

As we welcome a new year, we wish health, happiness, peace and success to all our partners, clients, healthcare professionals and friends around the world.

In 2026, we remain committed to supporting global healthcare by improving access to essential and specialty medicines, strengthening reliable supply chains, and working together for better patient outcomes.

May the new year bring good health, new opportunities and meaningful partnerships.
Happy New Year! 🌍💙

10/12/2025

🌟 Rapid-Acting Insulin for Mealtime Control – 100 IU/mL

Insulin Aspart is a recombinant rapid-acting insulin analogue engineered through a single amino-acid substitution (proline → aspartate at B28).
This modification reduces the molecule’s tendency to self-associate, resulting in faster absorption, quicker onset, and more predictable post-prandial glucose control compared to human regular insulin.

💊 Dosage Form: Insulin Aspart Injection, 100 IU/mL
🖊 Delivery System: Penfill-compatible cartridges
📦 Pack Size: 3 mL × 5 cartridges
🧬 Therapeutic Area: Diabetes / Endocrinology

✅ Key Highlights

• Ultra-rapid pharmacokinetics due to reduced hexamer formation
• Begins acting within minutes → ideal for post-meal glucose spikes
• Provides lower variability vs. conventional human insulin
• Suitable for basal–bolus therapy or flexible bolus-only regimens
• Widely used in Type 1 and Type 2 diabetes management across clinical settings
• High demand in global cold-chain insulin distribution networks

🌍 Supporting Global Access

Ancanex Pharma Trading FZCO works with hospitals, diabetes centers, government tenders, and licensed wholesalers to support reliable distribution of essential insulin therapies through GDP-compliant cold chain logistics.

⚠️ Disclaimer: This post is for professional and informational purposes only.
All trademarks belong to their respective owners.

18/11/2025

📢 CAPLACIZUMAB 10 mg/1 mL

Recombinant, Humanized Nanobody for TTP

Caplacizumab is a targeted therapy used in the management of acquired Thrombotic Thrombocytopenic Purpura (aTTP), a rare and life-threatening hematologic emergency requiring rapid intervention.

🩸 Mechanism of Action:
Targets von Willebrand factor, reducing microvascular platelet adhesion and preventing organ damage.

💉 Indication:
Treatment of adults experiencing acute episodes of acquired TTP, in combination with plasma exchange and immunosuppression.

📦 Dosage Form: Injection – 10 mg / 1 mL
📊 Route: Intravenous loading dose, followed by daily subcutaneous administration
📆 Typical Duration: Throughout plasma exchange + 30 days post-exchange (may be extended)

🔑 Key Highlights

• First-in-class targeted nanobody therapy for aTTP
• Helps normalize platelet count faster than standard therapy alone
• Reduces risk of recurrence and TTP-related mortality
• Widely required in hematology and critical care centers
• High global procurement demand – limited availability

🌍 Global Supply & B2B Availability

Ancanex Pharma Trading FZCO supports international wholesale requests for rare disease and specialty biologics through validated GDP pathways.

Suitable for:
✔ Licensed distributors
✔ Hospitals & infusion centers
✔ Government tenders
✔ Early access & named-patient programs

Disclaimer: This post is for professional and informational purposes only.

17/11/2025

🌟 Targeted Antibody-Drug Conjugate for HER2+ Breast Cancer – 100 mg / 160 mg Vials

A highly specialized antibody-drug conjugate (ADC) designed to deliver cytotoxic therapy directly to HER2-positive cancer cells. By combining monoclonal antibody targeting with a linked cytotoxic payload, this medicine provides selective tumor cell killing while minimizing systemic exposure.

💊 Dosage Forms:
• 100 mg lyophilized powder for infusion
• 160 mg lyophilized powder for infusion

💉 Administration: Intravenous infusion every 3 weeks
📦 Pack Size: Single-dose vial
🧬 Therapeutic Area: Oncology – HER2-positive breast cancer

⸻

✅ Key Highlights

• Antibody-drug conjugate targeting HER2 receptors
• Selective intracellular delivery of cytotoxic payload
• Standard of care in certain HER2+ advanced breast cancer settings
• Used in major cancer centers worldwide
• High demand for international named-patient supply programs

⸻

🌍 Supporting Global Access

Ancanex Pharma Trading FZCO provides licensed oncology products through verified international wholesale and import/export channels – serving hospitals, distributors, and government tenders.

Ancanex Pharma Trading FZCO

17/03/2026

16/02/2026

13/02/2026

12/02/2026

04/02/2026

22/01/2026

07/01/2026

05/01/2026

25/12/2025

10/12/2025

18/11/2025

17/11/2025

Address

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Featured

Share

Category